← Eichor
Study identifier: NCT07188610 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

Condition: CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma  ·  Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

PhasePhase 2
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

\*\*Translation:\*\* This clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells. Following lymphodepletion pretreatment, a single infusion of PA3-17 injection will be administered. Blood samples will be collected from the subjects before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations. In addition to the baseline period, the treatment phase will involve efficacy assessments at 4 weeks, 2 months, 3 months, and every 3 months thereafter, up to 24 months post-cell infusion. Tumor assessments will continue until disease progression (PD), initiation of new antitumor treatment, death, unacceptable toxicity, investigator decision, or subject's voluntary withdrawal, whichever occurs first.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaojun Huang, MD  ·  +86-13701389625  ·  xjhrm@medmail.com.cn

Mingzhi Zhang, MD  ·  037166295562  ·  mingzhi_zhang@126.com

Always discuss trial participation with your own doctor first.

Locations (16)

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)Hefei, Anhui, ChinaRecruiting
Peking University People's HospitalBeijing, Beijing Municipality, ChinaRecruiting
Peking University Third HospitalBeijing, Beijing Municipality, ChinaRecruiting
Sun Yat-sen University Cancer Center (SYSUCC)Guangzhou, Guangdong, ChinaRecruiting
Facility Name: Guangdong Provincial People's HospitalGuangzhou, Guangdong, ChinaNot Yet Recruiting
The First Hospital of HarbinHarbin, Heilongjiang, ChinaNot Yet Recruiting
Henan Cancer HospitalZhengzhou, Henan, ChinaRecruiting
The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, Henan, ChinaRecruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, ChinaRecruiting
Jiangsu Province HospitalNanjing, Jiangsu, ChinaRecruiting
The First Affiliated Hospital of Soochow UniversitySuzhou, Jiangsu, ChinaRecruiting
The Affiliated Hospital of Xuzhou Medical UniversityXuzhou, Jiangsu, ChinaRecruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07188610